Product Hopping in the Drug Industry - Lessons from Albuterol
NEW ENGLAND JOURNAL OF MEDICINE(2022)
摘要
Product Hopping in the Drug Industry Product hops to albuterol inhalers containing hydrofluoroalkane rather than chlorofluorocarbons cost payers and patients billions of dollars. Without patent and regulatory reform, this pattern is likely to be repeated.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要